Jim brings over three decades of extensive experience developing and commercializing vaccines intended to treat or prevent diseases that impact children and adults around the world. During this time, he held significant leadership positions in the vaccine divisions of Pfizer, Novartis and Merck. Prior to joining Vaxcyte, Jim served as the business unit lead for Pfizer Vaccines with a span of responsibility across market access, policy, pricing, tender negotiations, epidemiology and health outcomes for the entire portfolio, including the pneumococcal conjugate vaccine franchise (Prevnar 13®). Jim was also a long-tenured leader at Novartis where he led the development and launch of Menveo, a meningococcal conjugate vaccine; Bexsero®, a meningitis B vaccine; and the meningococcal ABCWY vaccine candidate. Previously, he led international marketing for the pediatric vaccine franchise at Merck Vaccines where he launched RotaTeq®, a vaccine for rotavirus gastroenteritis in infants, and held other technical and operational roles of increasing responsibility within research, manufacturing, quality, regulatory and technology transfer.
Jim earned a Bachelor of Science degree in chemistry/biology, with high honors, from the University of Notre Dame. He went on to get a Master of Science degree in bio-organic chemistry and a Master of Business Administration degree from Lehigh University. In 2014, James received the VIVA Award as Novartis’ top scientist in 2014 for development and approval of Bexsero®. He also was an ACE Finalist (Secretary of State Award for Corporate Excellence) for his role in conducting an effectiveness study of RotaTeq in Nicaragua.
What is Jim Wassil's net worth?
The estimated net worth of Jim Wassil is at least $7.14 million as of March 3rd, 2025. Mr. Wassil owns 154,931 shares of Vaxcyte stock worth more than $7,137,671 as of December 5th. This net worth approximation does not reflect any other assets that Mr. Wassil may own. Learn More about Jim Wassil's net worth.
How do I contact Jim Wassil?
Has Jim Wassil been buying or selling shares of Vaxcyte?
Jim Wassil has not been actively trading shares of Vaxcyte during the last quarter. Most recently, Jim Wassil sold 8,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a transaction totalling $586,160.00. Following the completion of the sale, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at $11,351,794.37. Learn More on Jim Wassil's trading history.
Who are Vaxcyte's active insiders?
Vaxcyte's insider roster includes Elvia Cowan (SVP), Mikhail Eydelman (SVP), Jeff Fairman (VP), Halley Gilbert (Director), Andrew Guggenhime (CFO), Teri Loxam (Director), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.
Are insiders buying or selling shares of Vaxcyte?
In the last year, insiders at the sold shares 9 times. They sold a total of 61,616 shares worth more than $5,225,971.00. The most recent insider tranaction occured on March, 3rd when COO Jim Wassil sold 8,000 shares worth more than $586,160.00. Insiders at Vaxcyte own 3.1% of the company.
Learn More about insider trades at Vaxcyte. Information on this page was last updated on 3/3/2025.
